摘要
目的研究口服丙戊酸钠（VPA）抗癫痫后，患儿的体重指数与清除率和消除半衰期药代动力学参数的相关性。方法选取20例癫痫患儿，10例为正常体重患儿，10例为超常体重（BMI超过正常20％及以上）患儿，测定口服VPA治疗后两组患儿的清除率和消除半衰期，比较药物清除特点。结果超常体重患儿的血药峰浓度有8例超过110mg／L，而正常体重儿童血药峰浓度最高110mg／L。正常体重的消除半衰期和清除率分别为（7．80±0．75）h和（O．18±0．03）L／h；超常体重患儿的消除半衰期和清除率分别为（9．50±0．63）h和（0．11±0．03）L／h。超常体重患儿比正常体重患儿的消除半衰期长，清除率低。结论体重与清除率和消除半衰期等药代动力学参数有相关性。超常体重VPA的代谢速度较正常体重患儿慢。
Objective To examine correlation between body mass index （BMI） and parameters of pharmacokinetics of pediatric patients after treatment with peroral sodium valproate. Methods Twenty pediatric patients[ 10 with norreal body weight, 10 with overweight （BMI 〉 20% higher than normal） ] with epilepsy were included. Elimination half life （T1/2） and clearance （CL） of patients were compared between the two groups after treatment with peroral sodium valproate. Results Blood drug levels of eight in the ten patients with overweight were over 110 mg/L; the maximum of blood drug peak concentration of patients with normal body weight was 110 mg/L. T1/2 and CL of patients with normal body weight was （7.80 ± 0.75） h and （0.18 ± 0.03） L/h, respecively, while T1/2 and CL of patients with overweight was （9.50±0.63 ） h and （0. 11 ± 0.03） L/h, respectively. TI/2 of patients with overweight was longer than patients with normal body weight, while CL was lower. Conclusion Body weight and parameters of pharmacokinetics are correlated. The clearance rate of pemral sodium valproate in patients with overweight is slower than patients with normal body weight.
出处
《中国生育健康杂志》
2012年第1期4-5,8,共3页
Chinese Journal of Reproductive Health
基金
黑龙江省教育厅科技技术研究项目（编号：10553057）
关键词
丙戊酸钠
体重指数
清除率
消除半衰期
Sodium valproate
Body mass Index
Clearance
Elimination half life
